Roche Partners with Zealand Pharma in $1.65 Billion Deal to Target the Obesity Market with Innovative Treatment Solution March 12, 2025
Roche Expands Obesity Drug Portfolio with $1.65 Billion Licensing Agreement for Promising Treatment Petrelintide March 12, 2025
Leadership Shakeup at FDA’s Device Division: Douglas Kelly’s Departure Sparks Questions on Regulatory Stability March 12, 2025
Viking Therapeutics Secures $150 Million Manufacturing Deal to Propel VK2735 in Obesity Drug Race March 12, 2025
Viking Therapeutics Secures Manufacturing Agreement to Propel VK2735 Obesity Drug Amid Market Uncertainty March 11, 2025
Viking Therapeutics Secures $150 Million Manufacturing Deal to Propel Weight Loss Drug VK2735 into Phase 3 Trials March 11, 2025
Breakthrough Genetic Therapy Shows Promise in Treating Rare Genetic Disorder Affecting Liver and Lungs March 11, 2025
Beam Therapeutics’ BEAM-302 Shows Promising Results in Pioneering Genetic Therapy for Alpha-1 Antitrypsin Deficiency March 11, 2025
Revolutionary Gene Therapy by Beam Therapeutics Shows Promising Results in Treating Alpha-1 Antitrypsin Deficiency March 11, 2025
